Industry News

Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement

The company will commence a tender offer to acquire all outstanding shares of Revance’s common stock for $3.10 per share in cash.

Author Image

By: Lianna Albrizio

Associate Editor

Crown Laboratories, Inc., a privately held, global innovative leader in the skincare industry, and Revance Therapeutics, Inc., a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings, have amended and restated the merger agreement entered into by the parties on Aug. 11, 2024, with aim to merge the two organizations. Under the terms of the amended and restated merger agreement, which has been unanimously approved by Revance’s ...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters